← Back to Search

PD-1 Inhibitor

Single Arm - Pembrolizumab for Endometrial Cancer

Q: What conditions are usually treated with Single Arm - Pembrolizumab?

This clinical trial is a single arm involving pembrolizumab to treat various malignant neoplasms, such as unresectable <a href="https://www.withpower.com/clinical-trials/melanoma">melanoma</a>, microsatellite instability high, and conditions resulting from chemotherapy treatment progression.

Q: Has Single Arm - Pembrolizumab previously been tested in any other medical research programs?

Currently, 962 research projects are underway in regards to the efficacy of Single Arm - Pembrolizumab. Of those trials, 122 have reached Phase 3 testing. Moreover, while Houston is a major hub for this treatment's clinical trials, there are 35k+ locations running studies on it around the world.

Q: Is this clinical trial currently open to enrollment?

Affirmative. Clinicaltrials.gov indicates that this scientific trial, which was first listed on March 29th 2019, is currently recruiting participants. Approximately 20 patients are required from one medical centre for the study to proceed as planned.

Q: How many participants are currently involved with this scientific investigation?

Affirmative. Clinicaltrials.gov provides evidence that applications are being accepted for this clinical trial, which was initially published on March 29th 2019 and most recently updated September 27th 2022. 20 individuals need to be enrolled from 1 site across the country.

Phase < 1

Waitlist Available

Led By Victoria Bae-Jump, MD

Research Sponsored by UNC Lineberger Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 weeks

Awards & highlights

Study Summary

This trial is testing whether the addition of pembrolizumab to standard adjuvant chemotherapy improves outcomes for patients with endometrial cancer.

Eligible Conditions

Endometrial Cancer
Uterine Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in the number of Tumor Infiltrating Lymphocytes

Secondary outcome measures

Change in number of Tumor Infiltrating Lymphocytes by endometrial cancer sub-types

Correlation of Immune and Obesity/Inflammation EC Signatures with TILs

Correlation of Microbiota Profiles with TILs

+3 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Single Arm - PembrolizumabExperimental Treatment2 Interventions

Single dose of Pembrolizumab 200mg IV administered prior to hysterectomy and surgical staging.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 2

~2010

Hysterectomy

2021

Completed Phase 3

~1440

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor

351 Previous Clinical Trials

88,329 Total Patients Enrolled

9 Trials studying Endometrial Cancer

327 Patients Enrolled for Endometrial Cancer

Merck Sharp & Dohme LLCIndustry Sponsor

3,887 Previous Clinical Trials

5,054,691 Total Patients Enrolled

19 Trials studying Endometrial Cancer

4,140 Patients Enrolled for Endometrial Cancer

Victoria Bae-Jump, MDPrincipal InvestigatorUNC-Chapel Hill

1 Previous Clinical Trials

32 Total Patients Enrolled

1 Trials studying Endometrial Cancer

32 Patients Enrolled for Endometrial Cancer

Media Library

Pembrolizumab (PD-1 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03694834 — Phase < 1

Endometrial Cancer Research Study Groups: Single Arm - Pembrolizumab

Endometrial Cancer Clinical Trial 2023: Pembrolizumab Highlights & Side Effects. Trial Name: NCT03694834 — Phase < 1

Pembrolizumab (PD-1 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03694834 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What conditions are usually treated with Single Arm - Pembrolizumab?

"This clinical trial is a single arm involving pembrolizumab to treat various malignant neoplasms, such as unresectable melanoma, microsatellite instability high, and conditions resulting from chemotherapy treatment progression."

Answered by AI

Has Single Arm - Pembrolizumab previously been tested in any other medical research programs?

"Currently, 962 research projects are underway in regards to the efficacy of Single Arm - Pembrolizumab. Of those trials, 122 have reached Phase 3 testing. Moreover, while Houston is a major hub for this treatment's clinical trials, there are 35k+ locations running studies on it around the world."

Answered by AI

Is this clinical trial currently open to enrollment?

"Affirmative. Clinicaltrials.gov indicates that this scientific trial, which was first listed on March 29th 2019, is currently recruiting participants. Approximately 20 patients are required from one medical centre for the study to proceed as planned."

Answered by AI

How many participants are currently involved with this scientific investigation?

"Affirmative. Clinicaltrials.gov provides evidence that applications are being accepted for this clinical trial, which was initially published on March 29th 2019 and most recently updated September 27th 2022. 20 individuals need to be enrolled from 1 site across the country."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer

2019. "Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03694834.